Huya Bioscience International LLC, of San Diego, said the Japanese Pharmaceutical and Medical Devices Agency accepted its accelerated development strategy for cancer drug HBI-8000, in development for the treatment of adult T-cell leukemia/lymphoma and peripheral T-cell lymphoma in Japan. HBI-8000 is a next-generation HDAC inhibitor.